Pfizer Inc.
PFE
$26.12
$0.1750.68%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/29/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 63.63B | 60.43B | 56.22B | 55.95B | 59.55B |
| Total Other Revenue | -- | 1.91B | 1.91B | 1.91B | 3.97B |
| Total Revenue | 63.63B | 60.43B | 56.22B | 55.95B | 59.55B |
| Cost of Revenue | 16.42B | 17.94B | 21.98B | 22.28B | 23.99B |
| Gross Profit | 47.21B | 42.49B | 34.25B | 33.67B | 35.56B |
| SG&A Expenses | 14.76B | 14.15B | 14.15B | 13.92B | 13.85B |
| Depreciation & Amortization | 5.29B | 5.19B | 5.06B | 4.94B | 4.73B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.28B | 47.88B | 51.89B | 51.80B | 53.25B |
| Operating Income | 16.34B | 12.55B | 4.33B | 4.14B | 6.30B |
| Income Before Tax | 8.02B | 3.90B | -4.16B | -1.79B | 1.06B |
| Income Tax Expenses | -28.00M | -402.00M | -1.60B | -1.54B | -1.12B |
| Earnings from Continuing Operations | 8.05K | 4.31K | -2.56K | -254.00 | 2.17K |
| Earnings from Discontinued Operations | 11.00M | -22.00M | -2.00M | -21.00M | -15.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -31.00M | -32.00M | -30.00M | -34.00M | -39.00M |
| Net Income | 8.03B | 4.25B | -2.60B | -309.00M | 2.12B |
| EBIT | 16.34B | 12.55B | 4.33B | 4.14B | 6.30B |
| EBITDA | 23.34B | 19.43B | 11.01B | 10.66B | 12.56B |
| EPS Basic | 1.42 | 0.75 | -0.46 | -0.06 | 0.38 |
| Normalized Basic EPS | 1.63 | 1.19 | 0.39 | 0.43 | 0.79 |
| EPS Diluted | 1.42 | 0.74 | -0.47 | -0.07 | 0.36 |
| Normalized Diluted EPS | 1.62 | 1.18 | 0.38 | 0.43 | 0.77 |
| Average Basic Shares Outstanding | 22.66B | 22.64B | 22.62B | 22.60B | 22.57B |
| Average Diluted Shares Outstanding | 22.80B | 22.75B | 22.69B | 22.70B | 22.73B |
| Dividend Per Share | 1.68 | 1.67 | 1.66 | 1.65 | 1.64 |
| Payout Ratio | 118.44% | 222.18% | -361.50% | -3,014.89% | 436.39% |
